Aydogdu I - Search Results

1

Prevention of oral mucositis due to 5-fluorouracil treatment with oral cryotherapy.

Baydar M, Dikilitas M, Sevinc A, Aydogdu I. Baydar M, et al. Among authors: aydogdu i. J Natl Med Assoc. 2005 Aug;97(8):1161-4. J Natl Med Assoc. 2005. PMID: 16173332 Free PMC article.

2

Enzyme Replacement Therapy in a Gaucher Family.

Erdem N, Buran T, Berber I, Aydogdu I. Erdem N, et al. Among authors: aydogdu i. J Natl Med Assoc. 2018 Aug;110(4):330-333. doi: 10.1016/j.jnma.2017.06.013. Epub 2017 Jul 14. J Natl Med Assoc. 2018. PMID: 30126557

3

Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group.

Beksac M, Haznedar R, Firatli-Tuglular T, Ozdogu H, Aydogdu I, Konuk N, Sucak G, Kaygusuz I, Karakus S, Kaya E, Ali R, Gulbas Z, Ozet G, Goker H, Undar L. Beksac M, et al. Among authors: aydogdu i. Eur J Haematol. 2011 Jan;86(1):16-22. doi: 10.1111/j.1600-0609.2010.01524.x. Epub 2010 Nov 22. Eur J Haematol. 2011. PMID: 20942865 Clinical Trial.

4

Retrospective analysis of patients with idiopathic thrombocytopenic purpura from Eastern Anatolia.

Kaya E, Erkurt MA, Aydogdu I, Kuku I, Ozhan O, Oner RI, Ulutas O. Kaya E, et al. Among authors: aydogdu i. Med Princ Pract. 2007;16(2):100-6. doi: 10.1159/000098360. Med Princ Pract. 2007. PMID: 17303943

5

Extramedullary myeloid leukemia mimicking lepromatous leprosy.

Sevinc A, Aydogdu I. Sevinc A, et al. Among authors: aydogdu i. J Natl Med Assoc. 2008 Sep;100(9):1036-8. doi: 10.1016/s0027-9684(15)31440-1. J Natl Med Assoc. 2008. PMID: 18807431

6

Development of large genital ulcer due to hydroxyurea treatment in a patient with chronic myeloid leukemia and Behcet's disease.

Karincaoglu Y, Kaya E, Esrefoglu M, Aydogdu I. Karincaoglu Y, et al. Among authors: aydogdu i. Leuk Lymphoma. 2003 Jun;44(6):1063-5. doi: 10.1080/1042819031000067864. Leuk Lymphoma. 2003. PMID: 12854911 Review.

7

Serum proinflammatory mediators at different periods of therapy in patients with multiple myeloma.

Kuku I, Bayraktar MR, Kaya E, Erkurt MA, Bayraktar N, Cikim K, Aydogdu I. Kuku I, et al. Among authors: aydogdu i. Mediators Inflamm. 2005 Aug 14;2005(3):171-4. doi: 10.1155/MI.2005.171. Mediators Inflamm. 2005. PMID: 16106104 Free PMC article.

8

Oxidant/antioxidant parameters and their relationship with medical treatment in multiple myeloma.

Kuku I, Aydogdu I, Bayraktar N, Kaya E, Akyol O, Erkurt MA. Kuku I, et al. Among authors: aydogdu i. Cell Biochem Funct. 2005 Jan-Feb;23(1):47-50. doi: 10.1002/cbf.1127. Cell Biochem Funct. 2005. PMID: 15386538 Clinical Trial.

9

Clinicopathologic characteristics and therapeutic outcomes of primary gastrointestinal non-Hodgkin's lymphomas: 10 years of experience from a single center in eastern Anatolia.

Erkurt MA, Aydogdu I, Kuku I, Kaya E, Basaran Y. Erkurt MA, et al. Among authors: aydogdu i. Med Princ Pract. 2009;18(5):399-406. doi: 10.1159/000226295. Epub 2009 Jul 31. Med Princ Pract. 2009. PMID: 19648764

10

Oxidant/antioxidant parameters and their relationship with chemotherapy in Hodgkin's lymphoma.

Kaya E, Keskin L, Aydogdu I, Kuku I, Bayraktar N, Erkut MA. Kaya E, et al. Among authors: aydogdu i. J Int Med Res. 2005 Nov-Dec;33(6):687-92. doi: 10.1177/147323000503300611. J Int Med Res. 2005. PMID: 16372587 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results